Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasound-Guided 5% Dextrose Hydrodissection Procedures for Persistent and Recurrent Post-Surgical Carpal Tunnel Syndrome: A Prospective Single-Center Cohort Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Baseline Neutrophil-to-Lymphocyte Ratio Stratifies Early Trichoscopic Response to Platelet-Rich Plasma-Based Regimens in Non-Scarring Alopecia: A Real-World Cohort with Internal Validation Using an Interpretable Neural Network.

Life (Basel, Switzerland)·2026
Same author

From Ultrasound to Histopathology: Agreement Analysis and Depth Correction Model for Basal Cell Carcinoma Using a Portable 20 MHz High-Frequency Ultrasound Device.

Diagnostics (Basel, Switzerland)·2026
Same author

Semi-Automated Lung Segmentation Based on Region-Growing Methods in Interstitial Lung Disease.

Journal of clinical medicine·2026
Same author

Acquired Reactive Perforating Collagenosis-A Rare Entity Occurring Within Common Disorders: A Systematic Review and Our Personal Experience.

Journal of clinical medicine·2026
Same author

Patient-Reported Outcomes on Quality of Life in Older Adults with Oral Pemphigus.

Healthcare (Basel, Switzerland)·2025

Related Experiment Video

Updated: May 31, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K

Cabozantinib Cutaneous Toxicity-Comprehensive Review.

Cristina Violeta Tutunaru1,2, Dragos Ovidiu Alexandru3, Sanda Amelia Dracea4,5

  • 1Department of Dermatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Life (Basel, Switzerland)
|January 25, 2025
PubMed
Summary

This review details skin toxicities from Cabozantinib, a cancer therapy drug. It outlines common side effects and management strategies to improve patient quality of life.

Keywords:
adverse effectscabozantinibcutaneous toxicitymedicationrenal cell carcinoma

More Related Videos

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Related Experiment Videos

Last Updated: May 31, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Systemic cancer therapies require effective management of adverse effects to maintain treatment efficacy and patient quality of life.
  • Cabozantinib is a multikinase inhibitor (MKI) approved for advanced kidney cancer, hepatocellular carcinoma, and medullary thyroid cancer.
  • Skin-related toxicities are common adverse events associated with multikinase inhibitors like Cabozantinib.

Purpose of the Study:

  • To provide a comprehensive overview of the dermatological side effects of Cabozantinib.
  • To identify and describe common skin toxicities associated with Cabozantinib treatment.
  • To suggest preventive and management strategies for these adverse effects based on their severity.

Main Methods:

  • Literature review of studies and clinical data on Cabozantinib and its associated dermatological toxicities.
  • Identification of common skin-related adverse events reported in clinical trials and real-world use.
  • Synthesis of current recommendations for managing Cabozantinib-induced skin toxicities.

Main Results:

  • Common skin toxicities include palmar-plantar erythrodysesthesia, stomatitis, hair alterations, xerosis, scrotal erythema, and subungual splinter hemorrhages.
  • The severity of these dermatological side effects can vary, impacting patient adherence and quality of life.
  • Evidence-based preventive measures and management guidelines are crucial for optimizing patient care.

Conclusions:

  • Effective management of Cabozantinib-induced skin toxicities is essential for maintaining treatment continuity and improving patient outcomes.
  • Understanding the spectrum of dermatological side effects allows for proactive intervention and supportive care.
  • This review provides a valuable resource for clinicians managing patients treated with Cabozantinib.